Latest Regulatory Compliance News

Percheron Therapeutics has raised $2.3 million through an institutional placement to fully fund its upcoming acute myeloid leukemia clinical trial led by Vanderbilt Health.

CurveBeam AI has secured over A$600,000 through its Share Purchase Plan, bolstering funds alongside a recent A$5 million placement. The capital will fuel the China launch and product development for its HiRise™ CT scanner.

Volt Group (ASX: VPR) is set to repurchase up to 5% of its shares over 12 months starting 16 September 2026, aiming to optimise capital structure without requiring shareholder approval.

RMA Global grew revenue 7% to $22.7 million in FY26, driven by US market gains and integration of Curated Social, but losses widened to $3.5 million. The company rebranded as Renowned and secured record US brokerage deals.

Osteopore Limited’s half-year results show an 8% revenue drop driven by currency effects, while losses widen 14% as the company invests heavily in product development and market growth.

BLS Pharmaceuticals (ASX: BLS) reported a standout FY26 with revenue surging 161% to $74.2 million and net profit more than tripling to $15.4 million, driven by expanded manufacturing and major international contracts including a $50 million German supply deal.

Clever Culture Systems expanded its pharmaceutical customer base to eight in FY26, placing 11 APAS Independence instruments and completing its product offering with a contact plate module. Despite a $2.24 million net loss, the company expects meaningful sales growth in FY27 backed by a robust pipeline and disciplined financial management.

Alterity Therapeutics has arranged an underwriting deal for up to 8.4 million ATHO options, potentially raising A$4.2 million to A$7.96 million ahead of their expiry. The funds aim to support the upcoming Phase 3 trial for ATH434 in Multiple System Atrophy and bolster working capital.

Atomo Diagnostics lifted revenue 41% to AUD 5.33 million for FY26, cutting its loss by 29% to AUD 3.51 million, driven by HIV self-testing growth and a key US partnership. Leadership changes signal a strategic pivot as the company eyes global expansion.

oOh!media and I Squared Capital have revised the definition of 'Superior Proposal' in their takeover agreement, setting a 3% premium threshold for competing bids within a four-week window from the scheme date.

5G Networks grew revenue by 13% to $71.4 million in FY26, buoyed by enterprise and cloud services including its cyber security acquisition AUCyber. Despite positive underlying EBITDA, net losses widened due to acquisition-related costs as the company pursues integration and data centre growth.

PT ANTAM (ASX:ATM) posted a 6% increase in net sales to Rp62.71 trillion in the first half of 2026, driven by steady gold, nickel, and bauxite sales. Profit after tax surged 34% to Rp6.91 trillion, supported by improved margins and foreign exchange gains.